Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
2024年8月7日 - 9:00PM
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or
“Company”), a clinical-stage pharmaceutical company developing
protein kinase inhibitor therapeutics to modify the course of
Parkinson's disease, Parkinson's-related disorders and other
diseases of the Abelson Tyrosine Kinases, today announced that it
will report financial results for the second quarter ended June 30,
2024, on Wednesday, August 14, 2024, after the close of U.S.
markets. Following the announcement, the Company will host a
conference call and webcast at 8:00 a.m. ET on Thursday, August 15,
2024, to provide a corporate update and review the financial
results.
The conference call can be accessed by dialing
1-877-407-0789 (United States) or 1-201-689-8562 (International)
and referencing Inhibikase Therapeutics. A live webcast may be
accessed using the link here, or by visiting the investors section
of the Company's website at www.inhibikase.com. After the live
webcast, the event will be archived on Inhibikase's website for
approximately 90 days after the call.
About Inhibikase
(www.inhibikase.com)
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage
pharmaceutical company developing therapeutics for Parkinson's
disease and related disorders. Inhibikase's multi-therapeutic
pipeline has a primary focus on neurodegeneration and its lead
program risvodetinib, an Abelson Tyrosine Kinase (c-Abl) inhibitor,
targets the treatment of Parkinson's disease inside and outside the
brain as well as other diseases that arise from Abelson Tyrosine
Kinases. Its multi-therapeutic pipeline is pursuing
Parkinson's-related disorders of the brain and GI tract, orphan
indications related to Parkinson's disease such as Multiple System
Atrophy, and drug delivery technologies for kinase inhibitors such
as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate
that the Company believes will provide a better patient experience
with fewer on-dosing side-effects. The Company's RAMP™ medicinal
chemistry program has identified several follow-on compounds to
risvodetinib that could potentially be applied to other cognitive
and motor function diseases of the brain. Inhibikase is
headquartered in Atlanta, Georgia with offices in Lexington,
Massachusetts.
Social Media
DisclaimerInvestors and others should note that the
Company announces material financial information to investors using
its investor relations website, press releases, SEC filings and
public conference calls and webcasts. The Company intends to also
use X, Facebook, LinkedIn and YouTube as a
means of disclosing information about the Company, its services and
other matters and for complying with its disclosure obligations
under Regulation FD.
Contacts:
Company Contact:Milton H. Werner, PhDPresident &
CEO678-392-3419info@inhibikase.com
Investor Relations:Alex LoboPrecision AQ
Alex.lobo@precisionaq.com
Inhibikase Therapeutics (NASDAQ:IKT)
過去 株価チャート
から 7 2024 まで 8 2024
Inhibikase Therapeutics (NASDAQ:IKT)
過去 株価チャート
から 8 2023 まで 8 2024